Tvardi Therapeutics(DE:69C)
€0.97-0.13 (-11.82%)
DE:69C
Tvardi Therapeutics stock forecast
€0.97
At close:-0.13 (-11.82%)
Tvardi Therapeutics (69C) Stock Forecast & Price Target
1 Followers
69C Analyst Ratings
Moderate Buy
5Buy1Hold1Sell
Based on 7 analysts giving stock ratings to Tvardi Therapeutics in the past 3 months
69C Stock 12 Month Forecast
Average Price Target
€7.38▲(661.04% Upside)Based on 7 Wall Street analysts offering 12 month price targets for Tvardi Therapeutics in the last 3 months. The average price target is EUR 7.38 with a high forecast of EUR 12.66 and a low forecast of EUR 2.71. The average price target represents a 661.04% change from the last price of EUR 0.97.
Past 12 Months12 Month ForecastJan2026Oct2026
High€12.66
Average€7.38
Low€2.71
Highest Price TargetHighest€12.66Average Price Target€7.38Lowest Price TargetLowest€2.71
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Sara Nik | H.C. Wainwright | €8.14 | buy | 738.70%Upside | Reiterated | 11/13/26 | ||
| Debanjana Chatterjee | JonesTrading | €9.04 | buy | 831.89%Upside | Reiterated | 11/08/26 | ||
| Gautam Chukka | Chardan Capital | €7.23 | buy | 645.51%Upside | Initiated | 10/20/26 | ||
| Elemer Piros | Lucid Capital | €5.42→€12.66 | buy | 1204.64%Upside | Initiated | 09/08/26 | ||
| Etzer Darout | Barclays | €2.71 | sell | 179.57%Upside | Reiterated | 08/20/26 | ||
| Julian Harrison | BTIG | €4.52 | buy | 365.94%Upside | Reiterated | 08/19/26 | ||
 Unknown AnalystNot Ranked | Cantor Fitzgerald | ― | hold | ― | Reiterated | 08/19/26 | ||
| Ryan Deschner | Raymond James | €9.04 | buy | 831.89%Upside | Upgraded | 07/08/26 | ||
| Yasmeen Rahimi | Piper Sandler | €11.75 | buy | 1111.45%Upside | Upgraded | 07/08/26 | ||
| Jay Olson | Oppenheimer | €9.04 | buy | 831.89%Upside | Reiterated | 05/11/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Sara NikH.C. Wainwright | BuyReiterated€8.14 | 11/13/26 | 738.70%Upside | ||
| Debanjana ChatterjeeJonesTrading | BuyReiterated€9.04 | 11/08/26 | 831.89%Upside | ||
| Gautam ChukkaChardan Capital | BuyInitiated€7.23 | 10/20/26 | 645.51%Upside | ||
| Elemer PirosLucid Capital | BuyInitiated€5.42→€12.66 | 09/08/26 | 1204.64%Upside | ||
| Etzer DaroutBarclays | SellReiterated€2.71 | 08/20/26 | 179.57%Upside | ||
| Julian HarrisonBTIG | BuyReiterated€4.52 | 08/19/26 | 365.94%Upside | ||
| Unknown AnalystCantor FitzgeraldNot Ranked | HoldReiterated | 08/19/26 | ― | ||
| Ryan DeschnerRaymond James | BuyUpgraded€9.04 | 07/08/26 | 831.89%Upside | ||
| Yasmeen RahimiPiper Sandler | BuyUpgraded€11.75 | 07/08/26 | 1111.45%Upside | ||
| Jay OlsonOppenheimer | BuyReiterated€9.04 | 05/11/26 | 831.89%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Tvardi Therapeutics
3 Months
Success Rate4/12 ratings generated profit
33%
Average Return
-10.97%
Copying Debanjana Chatterjee's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -10.97% per trade.
1 Year
Success Rate1/12 ratings generated profit
8%
Average Return
-61.60%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -61.60% per trade.
2 Years
Success Rate1/12 ratings generated profit
8%
Average Return
-63.57%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -63.57% per trade.
69C Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 12 | 8 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 0 |
| Sell | 3 | 5 | 5 | 3 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 13 | 17 | 18 | 12 | 6 |
In the current month, 69C has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 69C average Analyst price target in the past 3 months is 7.38.
69C Financial Forecast
High€-0.21
Consensus€-0.40
Low€-0.70
69C Earnings Forecast
Next quarter’s earnings estimate for 69C is -EUR 0.40 with a range of -EUR 0.70 to -EUR 0.21. The previous quarter’s EPS was -EUR 0.44. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€0.00
Consensus€0.00
Low€0.00
69C Sales Forecast
Next quarter’s sales forecast for 69C is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
69C Stock Forecast FAQ
What is DE:69C’s average 12-month price target, according to analysts?
Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is €7.38.
What is DE:69C’s upside potential, based on the analysts’ average price target?
Tvardi Therapeutics has 661.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Tvardi Therapeutics a Buy, Sell or Hold?
Tvardi Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 1 hold ratings and 1 sell ratings.
What is Tvardi Therapeutics’s share price target?
The average share price target for Tvardi Therapeutics is €7.38. This is based on 7 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €12.66, and the lowest forecast is €2.71. The average share price target represents a 661.04% increase from the current price of €0.97.
What do analysts say about Tvardi Therapeutics?
Tvardi Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Street analysts.
How can I buy shares of Tvardi Therapeutics?
To buy shares of DE:69C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
